摘要
胰腺癌早期诊断困难,预后差,患者5年生存率小于5%.新近研究报道,早期发现并切除的胰腺癌患者5年生存率为15%-40%,因此早期诊断胰腺癌能够有效挽救患者生命.目前一些常用的肿瘤标志物在胰腺癌的诊断、治疗监测及预后评估中起到了重要作用,但这些指标的特异性和敏感性尚不能满足,临床的需要.因此迫切需要寻找新的肿瘤标志物并建立联合诊断的方法来进一步提高胰腺癌的诊疗水平.
Pancreatic carcinoma is an almost uniformly lethal disease of humans and is associated with the lowest survival rate for any solid cancer, with only 5% of patients surviving 5 years after the diagnosis of pancreatic cancer. However, few effective methods can detect this kind of cancer at its early stage. The term “tumor marker” has been defined as “a naturally occurring molecule that is measured in serum or plasma, or other body fluids or in tissue extracts or in paraffin-embedded tissue to identify the presence of cancer, to assess patient prognosis, or to monitor a patient＇s response to therapy with the overall goal of improving the clinical management of the patient”. The greatest limitation of most studies of serum markers is that they fail to limit their analyses to patients with small, potentially curable pancreatic cancers. Therefore, it appears to be particularly urgent to explore new markers and establish novel diagnostic methods so as to achieve sufficient sensitivity and specificity. We discuss the advantages and disadvantages of different pancreatic tumor markers in improving the the diagnosis and treatment of pancreatic carcinoma.
出处
《世界华人消化杂志》
CAS
北大核心
2007年第34期3604-3610,共7页
World Chinese Journal of Digestology
